<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03881527</url>
  </required_header>
  <id_info>
    <org_study_id>2014/14OCT/513</org_study_id>
    <nct_id>NCT03881527</nct_id>
  </id_info>
  <brief_title>Nitinol Circular Blade</brief_title>
  <acronym>NCB</acronym>
  <official_title>Transaortic Native Valve Resection Using a Novel Nitinol Blade Device Rather Than a Classical Surgical Blade (Nitinol Circular Blade)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Nitinol Circular Blade (NCB) is indicated for use in patients with symptomatic aortic
      stenosis requiring aortic valve replacement, who are going to be operated by conventional
      sternotomy with native valve resection and replacement by a prosthetic aortic valve. The
      resection of the diseased leaflets will be performed by the NCB rather than conventional
      surgical blade.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patient will be under general anesthesia. The sternum will be opened fully or partially.
      The patient will be prepared for cardiopulmonary bypass. A transversal aortotomy will be
      performed as usual. The aortic valve will be exposed for the resection. The NCB will be
      inserted under visual control from the aorta to the left ventricle. The collection chamber
      will be closed and the circular blade can be advanced forward to resect the diseased native
      aortic valve. Once the resection is completed the device will be retrieved carefully.
      Complementary fine cleaning of the aortic annulus can be done by the surgeon in order to
      prepare the annulus to receive the prosthetic valve. After implantation of the new valve
      classically the aortotomy will be closed. Standard weaning of cardiopulmonary bypass will be
      done and the operation will be safely completed. The aim of this blade is to evaluate the
      resection time, test the efficiency of a circular Nitinol blade during resection of the
      calcified native aortic leaflets. A careful examination of the resection edges, aortic
      annulus, mitral valve and all surrounding tissues will be done in order to validate the
      efficacy of this Nitinol Circular Blade.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural success of the resection</measure>
    <time_frame>Hospital discharge : in average 1 week</time_frame>
    <description>Resection of the aortic valve leaflets by the circular nitinol blade</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complication due to the use of the device</measure>
    <time_frame>1 year</time_frame>
    <description>Any complication related to the use of the nitinol blade</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Resection of the aortic valve leaflets with device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in which the aortic valve has been resected using the nitinol blade</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Resection of the aortic valve leaflets in standard fashion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in which the aortic valve has been resected using a conventional blade or scissor</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aortic valve replacement using a nitinol blade</intervention_name>
    <description>A circular nitinol blade will be inserted by to cut the aortic valve leaflets during conventional aortic valve replacement procedure</description>
    <arm_group_label>Resection of the aortic valve leaflets with device</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>aortic valve replacement</intervention_name>
    <description>Aortic valve replacement in a standard fashion</description>
    <arm_group_label>Resection of the aortic valve leaflets in standard fashion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe aortic stenosis defined as one or more of the following by Doppler
             echocardiography: mean gradient &gt;40 mmHg; max velocity &gt;4 m/sec; aortic valve area
             &lt;=0.8 cm2.

          -  Symptoms related to aortic valve disease, and NYHA Functional Class II or greater

          -  Subject is indicated for aortic valve implantation with a biological prosthesis
             (tissue valve)

          -  Age &gt;= 65 years

          -  Echocardiographically determined aortic annulus diameter &gt;=24 mm and &lt;=30 mm in a
             long-axis view

          -  Subject understands the implications of participating in the study and provides
             informed consent

        Exclusion Criteria:

          -  Congenital unicuspid aortic valve

          -  Severe eccentricity of calcification, defined as calcium deposits larger than 6 mm in
             diameter

          -  Echocardiographic evidence of intracardiac mass, thrombus or vegetation

          -  Left ventricular ejection fraction &lt;25% as determined by contrast ventriculography, or
             echocardiography or radionuclide angiography if contrast ventriculography not
             available

          -  Hypertrophic obstructive cardiomyopathy

          -  Subjects with life expectancy less than 12 months due to an underlying non-cardiac
             co-morbid disease

          -  Known hypersensitivity or contraindication that cannot be adequately controlled with
             pre-medication to any study medication or material, such as contrast medium or Nitinol

          -  Blood dyscrasia such as acute anemia, leucopenia, or thrombocytopenia; bleeding
             diathesis, or coagulopathy

          -  Renal insufficiency assessed by creatinine &gt;2.5 mg/dl and/or end stage renal disease
             requiring chronic dialysis

          -  Poor lung function that in the investigator's opinion is prohibitive for thoracotomy

          -  Active peptic ulcer or GI bleeding within 3 months from the planned index procedure

          -  Cardiogenic shock, suspected cardiogenic shock, or hemodynamic instability requiring
             inotropic support or mechanical heart assistance

          -  Peripheral vascular disease, including abdominal and thoracic aortic disease, that
             could pose a problem for eventual transarterial mechanical support (e.g. intraaortic
             balloon pump)

          -  History of myocardial infarction in the last 6 weeks

          -  History of TIA or CVA in the last 6 months

          -  Subject refuses to have a blood transfusion

          -  Subject is currently enrolled in another investigational device or drug trial that may
             influence the outcome of this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Parla ASTARCI, Md PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universiatires St Luc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Parla ASTARCI, MD PhD</last_name>
    <phone>+32 2 764 64 12</phone>
    <email>parla.astarci@uclouvain.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emilano NAVARRA, MD</last_name>
    <phone>+32 764 61 07</phone>
    <email>emilano.navarra@uclouvain.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Parla ASTARCI</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Parla Astarci, MD PhD</last_name>
      <phone>+32 764 64 12</phone>
      <email>parla.Astarci@uclouvain.be</email>
    </contact>
    <investigator>
      <last_name>Parla ASTARCI, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <results_reference>
    <citation>Astarci P, Glineur D, Kefer J, Renkin J, Vanoverschelde JL, El Khoury G. &quot;Ring pledget&quot;: a new concept for secure apex closure during transapical aortic valve implantation. Innovations (Phila). 2010 Mar;5(2):136-7. doi: 10.1097/IMI.0b013e3181cbb364.</citation>
    <PMID>22437365</PMID>
  </results_reference>
  <results_reference>
    <citation>Astarci P, Glineur D, Kefer J, D'Hoore W, Renkin J, Vanoverschelde JL, El Khoury G, Grandin C. Magnetic resonance imaging evaluation of cerebral embolization during percutaneous aortic valve implantation: comparison of transfemoral and trans-apical approaches using Edwards Sapiens valve. Eur J Cardiothorac Surg. 2011 Aug;40(2):475-9. doi: 10.1016/j.ejcts.2010.11.070. Epub 2011 Jan 20.</citation>
    <PMID>21256045</PMID>
  </results_reference>
  <results_reference>
    <citation>Astarci P, Desiron Q, Glineur D, El Khoury G. Transapical explantation of an embolized transcatheter valve. Interact Cardiovasc Thorac Surg. 2011 Jul;13(1):1-2. doi: 10.1510/icvts.2011.267757. Epub 2011 Apr 11.</citation>
    <PMID>21486757</PMID>
  </results_reference>
  <results_reference>
    <citation>Astarci P, Glineur D, Elkhoury G, Raucent B. A novel device for endovascular native aortic valve resection for transapical transcatheter aortic valve implantation. Interact Cardiovasc Thorac Surg. 2012 Apr;14(4):378-80. doi: 10.1093/icvts/ivr125. Epub 2012 Jan 9.</citation>
    <PMID>22235001</PMID>
  </results_reference>
  <results_reference>
    <citation>Astarci P, Price J, Glineur D, D'Hoore W, Kefer J, Elkhoury G, Grandin C, Vanoverschelde JL. Cerebral embolization during percutaneous valve implantation does not occur during balloon inflation valvuloplasty: prospective diffusion-weighted brain MRI study. J Heart Valve Dis. 2013 Jan;22(1):79-84.</citation>
    <PMID>23610993</PMID>
  </results_reference>
  <results_reference>
    <citation>Astarci P, Glineur D, De Kerchove L, El Khoury G. Transcatheter valve used in a bailout technique during complicated open mitral valve surgery. Interact Cardiovasc Thorac Surg. 2013 Oct;17(4):745-7. doi: 10.1093/icvts/ivt249. Epub 2013 Jun 28.</citation>
    <PMID>23814136</PMID>
  </results_reference>
  <results_reference>
    <citation>Astarci P, Etienne PY, Raucent B, Bollen X, Tranduy K, Glineur D, Dekerchove L, Noirhomme P, Elkhoury G. Transcatheter resection of the native aortic valve prior to endovalve implantation - A rational approach to reduce TAVI-induced complications. Ann Cardiothorac Surg. 2012 Jul;1(2):224-30. doi: 10.3978/j.issn.2225-319X.2012.06.15.</citation>
    <PMID>23977499</PMID>
  </results_reference>
  <results_reference>
    <citation>Nuis RJ, Sinning JM, Rodés-Cabau J, Gotzmann M, van Garsse L, Kefer J, Bosmans J, Yong G, Dager AE, Revilla-Orodea A, Urena M, Nickenig G, Werner N, Maessen J, Astarci P, Perez S, Benitez LM, Amat-Santos IJ, López J, Dumont E, van Mieghem N, van Gelder T, van Domburg RT, de Jaegere PP. Prevalence, factors associated with, and prognostic effects of preoperative anemia on short- and long-term mortality in patients undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2013 Dec;6(6):625-34. doi: 10.1161/CIRCINTERVENTIONS.113.000409. Epub 2013 Nov 26.</citation>
    <PMID>24280965</PMID>
  </results_reference>
  <results_reference>
    <citation>Gauthier C, Astarci P, Baele P, Matta A, Kahn D, Kefer J, Momeni M. Mid-term survival after transcatheter aortic valve implantation: Results with respect to the anesthetic management and to the access route (transfemoral versus transapical). Ann Card Anaesth. 2015 Jul-Sep;18(3):343-51. doi: 10.4103/0971-9784.159804.</citation>
    <PMID>26139739</PMID>
  </results_reference>
  <results_reference>
    <citation>Navarra E, Mosala Nezhad Z, Bollen X, Gielen CE, Mastrobuoni S, De Kerchove L, Raucent B, Astarci P. Endovascular resection of the native aortic valve before transcatheter aortic valve implantation: state of the art and review. Eur J Cardiothorac Surg. 2016 Sep;50(3):406-10. doi: 10.1093/ejcts/ezw027. Epub 2016 Mar 31. Review.</citation>
    <PMID>27032472</PMID>
  </results_reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>October 7, 2015</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

